Karuna Therapeutics (NASDAQ: KRTX)
Karuna Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Karuna Therapeutics Company Info
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.
News & Analysis
Why Shares of Karuna Therapeutics Were Up Wednesday
The clinical-stage biotech announced positive trial results for its lead therapy.
2 On-Fire Biotech Stocks That Are Crushing the Bear Market
The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.
Why Karuna Therapeutics Stock Is On Fire Today
The biotech's psych med hit the mark in a late-stage trial.
Why Karuna Therapeutics Stock Tumbled This Week
Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.
The Coronavirus Pandemic Will Delay 2020 IPOs
COVID-19 and initial public offerings don’t go well together.
Why Did Karuna Therapeutics Pop 26% in January?
The volatile biotech has been up and down since its massive gain back in November.
Why Karuna Therapeutics Shares Sank Today
The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.
These Were the 10 Best IPOs of 2019
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.